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Background: Pigmented villonodular synovitis (PVNS) is a rare locally aggressive tumor. PVNS is characterized in
most cases by a specific t(1;2) translocation, which fuses the colony stimulating factor-1 (CSF1) gene to the collagen
type VIa3 (COL6A3) promoter thus leading through a paracrine effect to the attraction of non-neoplastic
inflammatory cells expressing CSF1-receptor. Imatinib is a tirosin-kinase inhibitors (TKI) active against CSF1-receptor
whose activity in naïve PVNS was already described. We report on two PVNS patients who responded to imatinib
after failure to nilotinib, another CSF1-receptor inhibitor.
Methods: Since August 2012, 2 patients with progressive, locally advanced PVNS resistant to nilotinib (Patient 1:
man, 34 years; Patient 2: woman, 24 years) have been treated with second-line imatinib 400 mg/day. Both patients
are evaluable for response.
Results: Both patients are still on treatment (7 and 4 months). Patient 1 had a dimensional response by MRI after 2
months from starting imatinib, together with symptomatic improvement. In Patient 2 a metabolic response was
detected by [18F]fluorodeoxyglucose–positron emission tomography (PET) at 6 weeks coupled with tumor shrinkage
by MRI, and symptomatic improvement.
Conclusions: Imatinib showed antitumor activity in 2 patients with nilotinib-resistant PVNS. This observation
strengthen the idea that targeted agent with similar profile can give a different clinical result, as already described for
gastrointestinal stromal tumor (GIST) patients treated with the same agents. Molecular studies are needed to clarify the
biologic mechanism(s) underlying the response.
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Pigmented villonodular synovitis (PVNS) is a rare locally
aggressive tumors which generally arise from the
synovium in the knee and foot of young individuals.
Standard treatment is surgery, but in a proportion of
cases surgery fails to obtain definitive disease control [1].
Even if PVNS is a locally destructive benign process and
very few patients die of the disease, the resulting func-
tional impairments can be substantial. The activity of
imatinib in PVNS was first reported by Blay et al. in
2008 [2], and confirmed thereafter in a retrospective
series of 27 patients, with RECIST partial response (PR)* Correspondence: silvia.stacchiotti@istitutotumori.mi.it
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distribution, and reproduction in any mediumin 19% and stable disease in 74% [3]. Imatinib antitumor
effect is thought to be mediated by blockade of the
colony stimulating factor-1 receptor (CSF1R). In fact,
colony stimulating factor-1 (CSF1), i.e. CSF1R ligand, is
overexpressed in PVNS due to a specific t(1;2) transloca-
tion, which fuses the CSF1 gene to the collagen type VI
a3 (COL6A3) promoter. CSF1, in turn, attracts non-
neoplastic inflammatory cells expressing the CSF1 recep-
tor (CSF1R) through a paracrine effect [4]. CSF1 is an
inflammatory mediator which is present together with
its receptor (CSF1R) in human synovia. Notably, CSF1
expression was demonstrated at protein and mRNA level
both in translocated and in non translocated PVNS [5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Path evaluation of Patient 1, Hematoxilin and Heosin-
stained (H&H) section. Tumor biopsy consistent with the diagnosis
of PVNS. Histology shows a tumor characterized by a cleft-like space
growth lined by synovial-like cells (panel A, 50x original magnification,
red arrow) and a mixed cellular component made-up of mononuclear
round small and large discohesive cells (panel B, 100x magnificent
magnification, green arrows), rare osteoclast-like giant cells (panel
B, violet arrow), inflammatory cells (panel B, blue arrow).
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The first patient was a 34 years old male, carrying a left
knee diffuse-type PVNS treated with debulking surgery
elsewhere in 2007 and 2010. As shown in Figure 1,
pathologic evaluation of the surgical specimen detected
a tumor characterized by a cleft-like space growth lined
by synovial-like cells, and a mixed cellular component
made-up of mononuclear round small and large
discohesive cells, rare osteoclast-like giant cells, inflam-
matory cells. The mononuclear large cells evaluated by
immunohistochemistry (PDGRB: Cell Signaling, clone
4564s; CSF1R: Santa Cruz Biotechnology, clone sc-692)
looked positive for CSF1R expression and platelet-
derived growth factor receptor beta (PDGFRB) (Figure 2,
panel C and B, respectively). The phospho-receptor
tirosine kinase (phRTK) array using pair matched
cryopreserved material detected PDGFRB and CSFR1activation. When the disease progressed locally, the pa-
tient refused mutilating surgery. Nilotinib was started
within a European phase 2 clinical study in July 2011.
Tumor size did not change and disease-related symp-
toms did not improve. The disease progressed after 12
months. In the lack of any alternative standard option,
imatinib 400 mg/day was introduced in August 2012.
Subjective improvement was seen as from a few weeks
of therapy. A dimensional response was confirmed after
2 months by magnetic resonance imaging (MRI). Patient
is currently on treatment and progression-free at 7
months.
The second patient was a 24 years old female. Her
PVNS affected the right knee and was treated with sev-
eral surgeries from 2002. Due to symptomatic and radio-
logical local progression, she entered a prospective study
on nilotinib in February 2012. Slow disease progression
was observed, and nilotinib was stopped after 6 months.
Imatinib 400 mg/day was started in October 2012. At
that time, this patient had functional limitations, pain
and local inflammatory signs. After few weeks of
imatinib, symptomatic improvement was observed and
patient stopped pain therapy. [18F]fluorodeoxyglucose–
positron emission tomography (PET)/CT taken after 6
weeks of imatinib confirmed the response. In Figure 3,
baseline PET/CT showed a right knee PVNS marked by
a maximum standard uptake value (SUV-max) of 14.7 g/
ml at the most metabolically active nodule. After treat-
ment, PET/CT (Figure 3) detected an objective response
marked by 72% decrease in the tumor metabolic activity
(SUV-max 4.1 g/ml). The response was further con-
firmed by MRI, as described in Figure 4, with evidence
of tumor shrinkage and improvement of the synovial
effusion. Patient is well after 4 months and treatment is
ongoing.
This analysis was approved by the Institutional Ethics
Committee.
Discussion
We report on objective tumor responses we observed in
two patients with locally advanced diffuse-type PVNS
whom we treated with imatinib following lack of re-
sponse to nilotinib. In the first case, response to imatinib
was observed in a patient that initially got a tumor dis-
ease stabilization under nilotinib and further progressed
(i.e. secondary resistance to nilotinib), while the second
patient never responded to nilotinib (i.e. primary resist-
ance to nilotinib).
Imatinib is a tyrosine-kinase inhibitor with activity
against BCR-ABL, KIT, PDGFR, FLT3, RET, and CSFR1.
No prospective studies on imatinib in PVNS are avail-
able, while a European phase 2 study on nilotinib, an-
other CSF1R inhibitor, was completed in 2012, and
results were preliminarily reported with [6]. At a median
Figure 3 [18F]fluorodeoxyglucose (FDG) PET/CT tumor assessment of Patient 2. Baseline PET/CT maximum projection image (MIP) (panel
A1) showed abnormal FDG focal uptakes in the right knee PVN with a SUVmax of 14.7 g/ml, as detailed by fused PET/CT transaxial slice (panel
A2). After 6 weeks of treatment, PET/CT MIP (panel B1) and fused PET/CT transaxial slice (panel B2) showed a marked decrease of tumor FDG
uptake (SUVmax 4.1 g/ml, i.e. 72% reduction).
Figure 2 Path and phospho-receptor tirosine kinase (phRTK) array evaluation of Patient 1. The phRTK array analysis showed PDGFRB and
CSFR1 activation, as indicated in panel A by the red and blue arrows, respectively. Immunohistochemistry resulted positive for platelet-derived
growth factor receptor beta (PDGFRB) and colony-stimulating-factor1-receptor (CSF1R) expression (panel B and C, respectively).
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Figure 4 Magnetic resonance imaging (MRI) tumor assessment
of Patient 2. Sagittal contrast enhanced (ce) TSE T1 weighted (w)
MRI images at baseline showed a lesion located behind the rotula
(panel A). After 2 months of imatinib a decrease in tumor size was
detected (panel B).
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RECIST PR in one out of 49 patients treated with
nilotinib (7%), for a 12-week progression free rate (PFR)
of 88.9%. The assumption was that the two agents would
have displayed the same pattern of antitumor activity in
this rare disease, given their similar molecular profile
and their ability to inhibit CSFR1 at similar concentra-
tions [7]. However, the observation of tumor responses
to imatinib in nilotinib-resistant PVNS patients is chal-
lenging and deserve further investigations.
One hypothesis may be a less favorable pharmakokinetics
of nilotinib in these patients, compared to imatinib. Besides,
a molecular investigation of these patients would be very
helpful to look at polymorphisms of other targets of
imatinib and nilotinib in particular KIT and PDGFR. Indir-
ect effects of imatinib on tumor progression, mediated by
specific activities on tyrosine kinase receptors other than
CSM1R cannot be excluded in these models. In fact, also
PDGFRB was found to be activated in the two cases we
describe here. This differential activity of imatinib and
nilotinib may also be related to differential biochemical ac-
tivity of these agents on CSFR1. Indeed the side effect pro-
file of nilotinib and imatinib are slightly different, eg with
more periorbital oedema with imatinib. This indicates that
imatinib has a differential activity on some targets, includ-
ing possibly CSFR1. Finally, the immune response hypoth-
esis should be also evaluated. In fact, CSFR1 is an
inflammatory mediator and can work also as quite a potent
blocker of the immune response through the dendritic cells
[8], and the NK cells [9]. In addition to selectively inhibit
the tumor cells, imatinib was found to be able to induce
indirect effects on immune system by stimulating auto-
immune response. Therefore, it is tempting to speculate
that the action of imatinib in PVNS could be also related to
this indirect effect, already reported for gastrointestinal
stromal tumor (GIST) patients [10,11]. In diffuse-typePVNS this effect could be even more relevant given the
significant amount of inflammatory component detectable
in this disease.
Conclusion
A tumor response to imatinib was seen in two patients
with progressive nilotinib-resistant PVNS.
This observation strengthen the notion that targeted
agents with an expected similar molecular profile can
show a different clinical activity, as already described for
GIST patients treated with the same agents. Molecular
studies are needed to better understand the molecular
basis for the activity of imatinib in this disease.
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